The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer.

Cancer Med 2014 Apr 27;3(2):245-51. Epub 2014 Jan 27.

Department of Urology, Austin Health/University of Melbourne, Heidelberg, Victoria, Australia; Department of Surgery, Austin Health/University of Melbourne, Heidelberg, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Expression of hypoxia-inducible factor (HIF)1α increases the risk of castrate-resistant prostate cancer (CRPC) and metastases in patients on androgen deprivation therapy (ADT) for prostate cancer (PC). We aimed to investigate the effects of nonspecific HIF1α inhibitors (Digoxin, metformin, and angiotensin-2 receptor blockers) on development of CRPC and metastases while on ADT. A retrospective review of prospectively collected medical records was conducted of all men who had continuous ADT as first-line therapy for CRPC at the Austin Hospital from 1983 to 2011. Association between HIF1α inhibitor medications and time to develop CRPC was investigated using actuarial statistics. Ninety-eight patients meeting the criteria were identified. Eighteen patients (21.4%) were treated with the nonspecific HIF1α inhibitors. Both groups had similar characteristics, apart from patients on HIF1α inhibitors being older (70 years vs. 63.9 years). The median CRPC-free survival was longer in men using HIF1α inhibitors compared to those not on inhibitors (6.7 years vs. 2.7 years, P = 0.01) and there was a 71% reduction in the risk of developing CRPC (HR 0.29 [95% CI 0.10-0.78] P = 0.02) after adjustment for Gleason score, age, and prostate-specific antigen (PSA). The median metastasis-free survival in men on HIF1α inhibitors was also significantly longer compared to those on no inhibitors (5.1 years vs. 2.6 years, P = 0.01) with an 81% reduction in the risk of developing metastases (HR 0.19 [CI 0.05-0.76] P = 0.02) after adjustment for Gleason score, age, and PSA. Nonspecific HIF1α inhibitors appear to increase the progression-free survival and reduce the risk of developing CRPC and metastases in patients on continuous ADT.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987074PMC
April 2014

Publication Analysis

Top Keywords

hif1α inhibitors
28
nonspecific hif1α
16
crpc metastases
12
risk developing
12
prostate cancer
12
hif1α
9
inhibitors
9
002 adjustment
8
adjustment gleason
8
gleason score
8
metastases patients
8
score age
8
years years
8
men hif1α
8
continuous adt
8
compared inhibitors
8
inhibitors years
8
years 001
8
reduction risk
8
developing crpc
8

Altmetric Statistics

Similar Publications